No internet connection — showing the saved version of the page.

Hemab Therapeutic…

USUSD
← to the screener

Hemab Therapeutics Holdings, Inc. (US:COAG) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 1. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
ir.hemab.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Headquarters
CAMBRIDGE, United States
Management
Benny Sorensen
Employees
59
Shares outstanding
46.73 M as of 2026-10-30
DateSharesChange
31.07.202646.71 M+0.01%no significant change
08.05.202646.71 M
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
20.31 M
Market cap
1.94 B USD
Insiders
10.78%
Institutions
92.52%
Industry (SIC)
Biological Products, (No Diagnostic Substances)
P/E
loss
EPS
−3.55 USD
P/B
4.25
FCF
−77.5 M USD
Debt
1.03 M USD
negative FCF — not covered
Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
Net income
−27.3 M USD quarter
For the quarter to 30.09.2026
Revenue0 USD
− Expenses29.8 M USD
Net income−27.3 M USD
History by quarter
RevenueExpensesLoss
31.03.2025: Revenue 0 · Expenses 16.6 M · Operating profit −16.6 M · Net income −15.3 M30.06.2025: Revenue 0 · Expenses 16.1 M · Operating profit −16.1 M · Net income −12.2 M30.09.2025: Revenue 0 · Expenses 17.1 M · Operating profit −17.1 M · Net income −17.1 M31.03.2026: Revenue 0 · Expenses 23.6 M · Operating profit −23.6 M · Net income −22.7 M30.06.2026: Revenue 0 · Expenses 26.1 M · Operating profit −26.1 M · Net income −24.2 M30.09.2026: Revenue 0 · Expenses 29.8 M · Operating profit −29.8 M · Net income −27.3 M
03.202509.2026
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
9.19 USD · P/NAV 4.25
Balance sheet date30.09.2026
Assets443 M USD
− Liabilities13.4 M USD
= NAV (equity of the company's shareholders)429 M USD
= Tangible NAV429 M USD
Shares46 730 608
NAV per share9.19 USD
Tangible NAV per share9.19 USD
Share price (COAG)39.0600 USD
P/NAV4.25
NAV history
Balance sheet dateNAVNAV per share
30.09.2026429 M USD9.19 USD
30.06.2026454 M USD9.72 USD
31.03.2026−199 M USD−4.25 USD
31.12.2025−177 M USD−3.78 USD
30.09.2025−158 M USD−3.38 USD
30.06.2025−141 M USD−3.03 USD
31.03.2025−129 M USD−2.76 USD
31.12.2024−115 M USD−2.47 USD
Description

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksCOAGUSD39.06 +0.01%common stock

Price

US:COAG · USD
Hover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
RA Capital Management, L…16.72%7.81 M2026-06-30
Novo Holdings A/S (Benef…8.95%4.18 M2026-06-30
FMR, LLC7.92%3.7 M2026-06-30
Capital International In…7.72%3.6 M2026-06-30
Deep Track Capital, Lp7.71%3.6 M2026-06-30
SmallCap World Fund Inc7.51%3.51 M2026-09-30
Siren, L.L.C.4.47%2.09 M2026-06-30
Avoro Capital Advisors L…4.12%1.93 M2026-06-30
Bain Capital Life Scienc…3.53%1.65 M2026-06-30
JPMORGAN CHASE & CO2.47%1.15 M2026-06-30
Vanguard Capital Managem…1.67%780 7582026-06-30
VANGUARD INDEX FUNDS-Van…1.19%555 5432026-06-30
JPMorgan Trust II-JPMorg…1.14%531 3822026-06-30
Fidelity Mt. Vernon Stre…1.12%523 8532026-08-31
SPDR SERIES TRUST-State…1.1%514 8582026-09-30
iShares Trust-iShares Ru…1.08%506 7912026-09-30
Fidelity Capital Trust-F…0.94%439 9532026-07-31
Fidelity Select Portfoli…0.94%439 4762026-08-31
Fidelity Securities Fund…0.57%267 7542026-07-31
Fidelity Securities Fund…0.51%236 2002026-08-31
MARAGANORE JOHN M (Direc…≈0.08%35 9482026-05-04
RA CAPITAL HEALTHCARE FU…——2026-05-12